NYSE · PACS
PACS Group, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for PACS: Nov 03, 2026
PACS Group, Inc. Common Stock is expected to report earnings on 11/03/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $0.56. The reported EPS for the same quarter last year was $0.32.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.56 | $0.56 | $0.56 | 2 |
| Dec 2026 | $0.61 | $0.62 | $0.59 | 2 |
| Mar 2027 | $0.63 | $0.65 | $0.60 | 2 |
| Jun 2027 | $0.65 | $0.65 | $0.65 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · MarketBeat · The Motley Fool- Zacks · Oct 21, 4:50 PM EDTMedpace (MEDP) Q3 Earnings and Revenues Beat EstimatesMedpace (MEDP) delivered earnings and revenue surprises of +8.76% and +1.02%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 16, 6:52 AM EDTPACS Group, Inc. (PACS) Surges 6.2%: Is This an Indication of Further Gains?PACS Group, Inc. (PACS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
- Zacks · Sep 8, 11:40 AM EDTPACS Expands Florida Footprint With 32-Facility AcquisitionPACS plans to acquire operations of 32 Florida skilled nursing facilities, adding 4,049 licensed beds and establishing a statewide network.
- Zacks · Aug 27, 10:20 AM EDTHere's Why Ensign Group Stock Remains a Buy for InvestorsEnsign Group's rising occupancy, acquisitions and real-estate growth support its outlook, while reimbursement and cost pressures remain risks.
- Zacks · Aug 25, 4:53 AM EDTZacks Industry Outlook CareDx, BrightSpring and PACSCareDx, BrightSpring and PACS have been highlighted in this Industry Outlook article.
- Zacks · Aug 24, 9:24 AM EDT3 Medical Service Stocks Resilient Amid Persistent Workforce ShortageCareDx, BrightSpring and PACS Group are positioned for growth as digital health expands and workforce shortages reshape medical services.
- MarketBeat · Aug 19, 7:30 AM EDTAmid Legal Risks, This Company Is Still Rated a BuyWhen investors look for stocks riding the aging of America, they might look at hospital chains, pharmacy benefit managers, or dividend-paying healthcare REITs. What few might expect is PACS Group (NYSE: PACS), a skilled nursing operator whose stock fell more than 80% in a year
- Zacks · Aug 13, 9:55 AM EDTWall Street Analysts See a 25.73% Upside in PACS Group, Inc. (PACS): Can the Stock Really Move This High?The consensus price target hints at a 25.7% upside potential for PACS Group, Inc. (PACS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- The Motley Fool · Aug 11, 8:13 PM EDTPACS (PACS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 11, 9:15 AM EDTBiodesix, Inc. (BDSX) Hit a 52 Week High, Can the Run Continue?Biodesix (BDSX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- MarketBeat · Aug 8, 8:03 PM EDTPACS Group Q2 Earnings Call HighlightsPACS Group (NYSE:PACS) reported second-quarter 2026 revenue growth of 9.1% and adjusted EBITDA growth of 25% from a year earlier, citing higher occupancy, improved skilled nursing patient mix and continued progress across acquired facilities as they mature within its operating mo
- Zacks · Aug 4, 7:00 PM EDTPACS Group, Inc. (PACS) Surpasses Q2 Earnings and Revenue EstimatesPACS Group, Inc. (PACS) delivered earnings and revenue surprises of +14.55% and +1.07%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for PACS Group, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.